Farnext announces the completion of the consolidation of its shares at the price of one new share compared to the old 5000, and the start of trading the shares resulting from the consolidation as of Wednesday, November 23, 2022, as well as the capital reduction – 11/22/2022 at 6:00 pm

Paris, France, November 22, 2022, 6:00pm (CET) – Farnext SA (FR001400BV89 – ALPHA) (the “Company”), an advanced clinical-stage biopharmaceutical company developing new therapies for neurodegenerative diseases without a satisfactory therapeutic solution , announces today, today, the consolidation of its shares as decided by its Board of Directors on September 26, 2022, at the rate of one new share with a nominal value of 1 euro compared to 5,000 old shares with a nominal value of 0.0002 euro, as authorized by the general meeting on June 17, 2022 under the provisions of Its eighth decision.